Treatment Approach for Rate-Controlled Atrial Flutter

Acute Management Options

The American Heart Association recommends beta blockers, diltiazem, or verapamil as first-line agents for maintaining rate control in hemodynamically stable patients with atrial flutter 3, 4
Intravenous diltiazem is the preferred calcium channel blocker for acute rate control due to its safety and efficacy profile, as recommended by the American College of Cardiology 3
Esmolol is generally the preferred intravenous beta blocker for acute rate control because of its rapid onset, according to the American Heart Association 3
For patients with systolic heart failure where beta blockers are contraindicated or ineffective, intravenous amiodarone can be useful for acute rate control, as suggested by the Heart Rhythm Society 5
The American College of Cardiology advises avoiding diltiazem and verapamil in patients with advanced heart failure, heart block, or sinus node dysfunction without pacemaker therapy 3
The American Heart Association recommends avoiding beta blockers, diltiazem, and verapamil in patients with pre-excited atrial flutter due to risk of accelerated ventricular rates and ventricular fibrillation 4

Elective synchronized cardioversion is indicated in stable patients when a rhythm-control strategy is pursued, as recommended by the American College of Cardiology 2
Cardioversion for atrial flutter can be successful at lower energy levels than for atrial fibrillation, according to the Heart Rhythm Society 2
The American Heart Association suggests that appropriate anticoagulation should be considered before cardioversion 2
Oral dofetilide or intravenous ibutilide can convert atrial flutter to sinus rhythm in approximately 60% of cases, as reported by the American College of Cardiology 6, 7
Pretreatment with magnesium can increase ibutilide efficacy and reduce risk of torsades de pointes, according to the American Heart Association 6
Rapid atrial pacing is useful for acute conversion in patients with pacing wires already in place, as suggested by the Heart Rhythm Society 8

Catheter ablation of the CTI is the preferred definitive treatment for symptomatic atrial flutter or flutter refractory to pharmacological rate control, as recommended by the American College of Cardiology 9, 7
Ablation prevents development of tachycardia-mediated cardiomyopathy, according to the American Heart Association 2
Beta blockers, diltiazem, or verapamil are useful for long-term rate control, as suggested by the American College of Cardiology 4
Higher doses or combination therapy may be needed as rate control is often more difficult to achieve in atrial flutter than in atrial fibrillation, according to the Heart Rhythm Society 4
Amiodarone, dofetilide, or sotalol can be useful to maintain sinus rhythm in symptomatic recurrent atrial flutter, as recommended by the American College of Cardiology 2
Flecainide or propafenone may be considered only in patients without structural heart disease, according to the American Heart Association 7

Antithrombotic therapy should follow the same guidelines as for atrial fibrillation, as recommended by the American College of Cardiology 9
Risk of stroke in atrial flutter is significant, with reported rates of 3% annually, according to the American Heart Association 5

Rate control can be more difficult to achieve in atrial flutter than in atrial fibrillation due to less concealed AV nodal conduction, as reported by the American College of Cardiology 4
Atrial flutter and atrial fibrillation frequently coexist—22-50% of patients develop atrial fibrillation within 14-30 months after CTI ablation for atrial flutter, according to the American Heart Association 2
Risk factors for developing atrial fibrillation after atrial flutter ablation include prior atrial fibrillation, depressed left ventricular function, structural heart disease, and increased left atrial size, as suggested by the Heart Rhythm Society 2